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Abstract
The pathogenesis of splenic marginal zone lymphoma (SMZL) remains largely unknown. Recent high-throughput
sequencing studies have identified recurrent mutations in key pathways, most notably NOTCH2 mutations in >25% of
patients. These studies are based on small, heterogeneous discovery cohorts, and therefore only captured a fraction
of the lesions present in the SMZL genome. To identify further novel pathogenic mutations within related biochemical
pathways, we applied whole exome sequencing (WES) and copy number (CN) analysis to a biologically and clinically
homogeneous cohort of seven SMZL patients with 7q abnormalities and IGHV1-2*04 gene usage. We identified 173
somatic non-silent variants, affecting 160 distinct genes. In additional to providing independent validation of the
presence of mutation in several previously reported genes (NOTCH2, TNFAIP3, MAP3K14, MLL2 and SPEN), our
study defined eight additional recurrently mutated genes in SMZL; these genes are CREBBP, CBFA2T3, AMOTL1,
FAT4, FBXO11, PLA2G4D, TRRAP and USH2A. By integrating our WES and CN data we identified three mutated
putative candidate genes targeted by 7q deletions (CUL1, EZH2 and FLNC), with FLNC positioned within the well-
characterized 7q minimally deleted region. Taken together, this work expands the reported directory of recurrently
mutated cancer genes in this disease, thereby expanding our understanding of SMZL pathogenesis. Ultimately, this
work will help to establish a stratified approach to care including the possibility of targeted therapy.
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Introduction
Splenic Marginal Zone Lymphoma (SMZL) is a low grade
chronic B cell lymphoproliferative disorder that predominantly
affects elderly patients and involves the spleen, bone marrow,
and peripheral blood [1]. Although the median survival is
around 10 years, approximately 70% of SMZL patients require
treatment, of whom 25% experience progressive disease,
leading to early death [1].
Our understanding of the molecular pathogenesis of SMZL
remains limited. Early cytogenetic studies identified recurrent
deletions of 7q31-q32 and duplications of 3q in approx. 30%
and 20% of cases, respectively [2], but subsequent molecular
investigations have failed to identify causative genes within
these regions [3]. Candidate gene studies are limited to
mutations in TP53, which is disrupted in 10-15% of cases [2],
and to genes within the NF-ƘB pathway, which are mutated in
a third of all cases [4,5]. The presence of a highly restricted
immunoglobulin gene repertoire, in particular the selective
usage of the immunoglobulin heavy chain variable (IGHV)
1-2*04 allele in 20-30% of patients, suggests that antigenic
stimulation may be important in the pathogenesis of this
disease [6].
The recent application of whole exome sequencing to frozen
splenic tissue from 14 patients with SMZL followed by targeted
resequencing of recurrent variants in larger cohorts has
identified further biologically relevant genes [7,8]. Mutations in
NOTCH2, which eliminate the C-terminal PEST domain and
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result in compromised protein degradation, were identified in
20 - 25% of cases although there was no consensus as to the
clinical significance of these mutations between studies [7,8].
Gene mutations in modulators or other members of the Notch
signalling pathway and in other pathways, such as chromatin
remodelling and transcriptional regulation were also implicated
[8].
In view of the relatively small number of patients investigated
so far and the biological heterogeneity of SMZL, it is vital to
perform additional gene discovery experiments to fully
catalogue the molecular lesions that contribute to disease
pathogenesis. To this aim, we performed whole exome
sequencing and copy number analysis of tumour and germ-line
DNA extracted from a clinically homogeneous cohort of SMZL
patients. In doing so, we expand the reported directory of
recurrently mutated cancer genes in this disease, thereby
expanding our understanding of SMZL pathogenesis that will
ultimately facilitate improvements in disease management and
the promise of novel therapies.
Materials and Methods
Patients and biomarker analysis
Seven patients were included in this current study, all met
established diagnostic criteria [1], and 5/7 underwent a
splenectomy with histology typical of SMZL in each case and
no evidence of transformation to a high-grade lymphoma. Each
patients harboured chromosomal aberrations targeting 7q and
IGHV1-2*04 usage (Table S1), ensuring the exclusion of other
types of splenic lymphoma from our analysis and maximizing
the likelihood of identifying pathogenic mutations within related
biochemical pathways. Informed patient consent was obtained
according to the declaration of Helsinki, and the study was
ethically approved by the local REC.
Chromosomal analysis was performed and described
according to the International System for Human Cytogenetic
Nomenclature [9]. Immunoglobulin variable region genes were
sequenced from either cDNA or gDNA as previously described
[6]. cDNA was synthesised by reverse transcription according
to the manufacturers protocol (Promega). gDNA was extracted
using the Qiagen Blood Mini Kit and amplified using the
BIOMED 2 protocol [10]. PCR products were sequenced
directly using an ABI 310 genetic analyser and sequences
were aligned to the IMGT-V-Quest database.
High-throughput sequencing, variant calling and
Sanger validation
Using targeted exome capture (SureSelect Human All Exon
51Mb V4, 50Mb V3, Agilent) we prepared sequencing libraries
from high-molecular weight genomic DNA from CD19 positive-
purified tumour cells (five cases extracted from the spleen and
two from peripheral blood) and matched saliva cells (Oragene
DNA kit, DNA Genotek) prior to high-throughput sequencing
with the Illumina HiSeq system. The paired-end sequencing
data were aligned against the human genome reference
sequence (hg19/GRCh37) using the Novoalign software
(novoalignMPI V2.08.02, Novocraft Technologies, Selangor,
Malaysia). Duplicate reads, resulting from PCR clonality or
optical duplicates, and reads mapping to multiple locations
were excluded from downstream analysis. Depth and breadth
of sequence coverage was calculated with custom scripts and
the BedTools package (v2.13.2) [11] and is included in table
S2.
Germ-line-Tumour paired datasets were analysed to identify
single nucleotide variations (SNVs) and small insertion and
deletions using Varscan 2.3.3 [12] (http://
varscan.sourceforge.net). The minimum variant allele
frequency threshold was set to 10% with a minimum read
depth of 4. Variants were filtered using the ‘somaticFilter’
command to remove clusters of false positives and SNV calls
near indels with the same frequency and depth thresholds.
Variants were annotated with respect to genes and
transcripts and filtered using the Annovar software tool
(v2012Jun21) [13]. Variants were cross referenced with
databases of known variation were downloaded from the
Annovar website (June 2012); data from the 1000 Genomes
Project (2012 April release)[14], dbSNP135 (and a version with
SNPs flagged as rare <1% frequency or clinically associated by
NCBI) and data from 4300 European American samples from
The National Heart Lung and Blood Institute Exome
Sequencing Project Exome Variant Server (http://
evs.gs.washington.edu/EVS/), (ESP6500 release). Using
conventional Sanger sequencing, we confirmed the presence
of 38/45 somatic variants (84.4%) and those non-concordant
cases were due to low exome read-depth in the tumour
sample.
SNP6.0 array hybridization, data extraction and
analysis
Tumour and germ-line DNA was purified, amplified, labelled
and hybridized to the Affymetrix SNP6.0 platform (Affymetrix,
Santa Clara, CA) as previously described [15]. For copy
number analysis, two independent researchers visually
inspected parallel copy number profiles (aligned to hg19/
GRCh37) from tumour and germ-line samples using Partek
Genomics Suite (Partek Inc, Missouri, USA), and lesions were
classified as somatic if they were present and absent in the
tumour and germ-line material, respectively. Copy number
alterations (CNAs) were defined as a deviation of 50
consecutive array features (probes) from a normal value of 2
(±0.3), within a consecutive genomic window of 50 Kilobases.
The allele ratio was calculated for each sample using the
HapMap Allele Reference baseline (Affymetrix) and copy
number neutral loss of heterozygosity (CNNLOH) event were
defined as somatic if they were present and absent in the
tumour and germ-line material, respectively.
Results and Discussion
Exome-capture and high-throughput sequencing allowed us
to align approx. 41.9 million reads per sample at a mean depth
of 69x (range, 43-109x). In total, an average of 82.2% (range,
70-95%) of target sequences captured at 20x. Our analytical
pipeline identified 176 somatic non-silent variants, affecting 165
distinct genes (Table S2). These variants were base-pair
transitions (34%), transversions (28%), insertions (6%) and
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deletions (31%). Copy number analysis identified 28
somatically-acquired copy number deletions (66%) and
duplications (33%), (Table S2). Considering the mutation and
copy number data together, our patients exhibited an average
of 25 somatic mutations (range, 9-40) and four copy number
alterations (range, 2-9) per tumour sample.
We initially investigated our exome sequencing data for the
presence of somatic variants in genes known to be recurrently
mutated in SMZL. In doing so, we identified mutations in
NOTCH2 [exon 34, n=2], TNFAIP3 [n=3], MAP3K14 [n=2],
MLL2 [n=1] and SPEN [n=1] (Table 1). As the exome capture
efficiency of NOTCH2 can compromise variant identification,
we also performed Sanger sequencing of exon 34 as
previously reported [8]. In doing so, we found no additional
mutations. Furthermore, we identified mutations in six genes
that have previously been shown to harbour mutations in single
SMZL cases [8] (Table 1). This observation implicates these
genes as recurrent mutational targets in SMZL. Mutations in
several of these genes have been identified in other tumour
types, for example FBXO11, which is recurrently mutated in
diffuse large B-cell lymphoma (DLBCL) and promote
leukaemogenesis by stabilization of BCL6 [16] (Table 1).
Next we investigated our SMZL cases for recurrent
mutations in genes that have not been previously identified in
SMZL (Table 1). This analysis identified two genes, CREBBP
and CBFA2T3, both mutated in two patients, which in the
context of the published literature provides a potential
prevalence of approx. 10% in SMZL. Both of the CREBBP
mutations were the Y1412C variant previously identified in
DLBCL [17]. CREBBP is involved in chromatin remodelling and
transcription factor recognition, and this mutation has been
shown to compromise the protein’s ability to acetylate BCL6
and p53 [17]. The CBFA2T3 gene, a core binding factor from
the myeloid translocation gene family, is targeted by recurrent
chromosomal rearrangements in both lymphoid and myeloid
malignancies. Whilst non-synonymous in nature, our mutations
were not located within the key ETO, MTG16 or TAFH
functional domains of the protein. In pediatric B-cell lymphoma,
CBFA2T3 has been implicated as a cellular proto-oncogene as
in rare cases the gene is juxtaposed to the immunoglobulin
locus [18]. In AML chromosomal inversions involving CBFA2T3
can directly increase the self-renewal capacity of hematopoietic
progenitors [19]. Mutations in both these genes were present in
approx. 50% of reads, suggesting they are heterozygous
mutations present in the dominant tumour clone.
To further assess the potential biological impact of the
mutations observed in our cases, pathway analysis was
performed using the Database for Annotation, Visualisation and
Integrated Discovery (DAVID) (Table 2). In addition to
identifying pathways already implicated in SMZL pathogenesis,
such as notch signalling (NOTCH2, NOTCH4), we also show
that genes within MAPK signalling pathway are targeted by
Table 1. Summary of recurrently mutated genes in our cases and a comparison with previously published studies.
 Genes Accession Variant nomenclature SIFT score Polyphen-2 score Case no6. Published
  number   prediction prediction 1 2 3 4 5 6 7 Study
   Nucleotide change4 Amino acid change consequences consequences        7
ESTABLISHED: NOTCH2 NM_024408 c.C7081T° p.Q2361X Damaging Truncating     ✓   [7,8]
Genes   c.6836delA§ p.H2279fs Truncating Truncating ✓        
recurrently MAP3K14 NM_003954 c.C200G* p. A67G Damaging Probably damaging     ✓   [8]
mutated TNFAIP3 NM_006290 c.T1343A* p.M448K Tolerated Truncating      ✓  [4,5,8]
in SMZL1   c.C1681T* p. P561S Tolerated Truncating      ✓   
   c.A328T* p. T110S Tolerated Truncating    ✓     
 MLL2 NM_003482 c.2507_2508insC p.Q836fs Truncating Truncating      ✓  [8]
 SPEN NM_015001 c.C5179T° p.Q1727X Tolerated Truncating      ✓  [8]
   c.10286_10289del§ p.3429_3430del Truncating Truncating      ✓   
NOVEL: AMOTL1 NM_130847 c.G1270A* p.A424T Tolerated Benign      ✓  [8]
Recurrent FAT4 NM_024582 c.G6628A* p.A2210T Tolerated Benign ✓       [8]
genes across FBXO11 NM_001190274 c.G1587C* p.W529C Damaging Truncating    ✓    [8]
studies2 PLA2G4D NM_178034 c.23delG§ p.G8fs Truncating Truncating   ✓     [8]
 TRRAP NM_003496 c.367-10T>-^ Splicing5 Truncating Truncating     ✓   [8]
 USH2A NM_206933 c.G7553C* p.S2518T Tolerated Benign    ✓    [8]
NOVEL: CBFA2T3 NM_175931 c.C464T* p.P155L Damaging Probably damaging     ✓   Novel
recurrent   c.G1445A p. S482N Damaging Probably damaging       ✓  
genes in our study3 CREBBP NM_001079846 c.A4349G* p.Y1450C Damaging Truncating     ✓ ✓  Novel
1 Identifies those genes that have previously been shown to be targeted by recurrent mutations in SMZL. 2 Shows those genes that were mutated in single SMZL cases in
both our current study and in previously published work. 3 Shows the novel genes targeted by recurrent mutations in our study.
4 Identified non-synonymous (*), splice-site (^), frameshift (§) and stopgain (°) mutations
5 The TRRAP mutation in case 5 occurred within a splice-site and is predicted to resulted in aberrant splicing
6 Showed the presence (✓) and absence (white box) of each mutation in the patients in our series
7 Highlights the published studies that identified the mutations in each of the genes listed
doi: 10.1371/journal.pone.0083244.t001
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somatic non-synonymous mutations in the majority of our
cases (5/7, 71%). Whilst a biological role of these genes in
SMZL required functional confirmation, our data does suggest
that the MAPK signalling pathway is a major target for somatic
mutations in this sub-group of SMZL.
Finally, we identified somatically acquired mutations in genes
also targeted by 7q deletions in our patients. In doing so, we
found CUL1, FLNC and EZH2 mutations in individual cases
(Table 2). Of these gene mutations, only FLNC was located
within the published 7q MDR [3,20]. FLNC mutations have not
been previously identified in a series eight del(7q) cases [20],
suggesting that the prevalence of FLNC mutation is low in this
sub-type of SMZL. However, further research will be required
to establish if rare mutations represent only one mechanism of
gene deregulation, as repression of FLNC transcription by
promoter methylation in prevalent in several other human
cancer types [21-24]. The somatic variant we identified in EZH2
(p.K199N), which is located outside the SET protein domain, is
not the activating mutation prevalent in follicular lymphoma and
DLBCL [25] nor has it been previously reported in AML or MDS
[26].
Herein, for the first time, we report the analysis of a
homogeneous cohort of SMZL cases using whole exome
sequencing and copy number analysis. In doing so, we validate
the presence of recurrent mutations in several genes with
established importance in SMZL. Furthermore, we expand the
reported directory of recurrently mutation cancer genes in this
disease, with the most significant observation being the
identification of recurrent mutations in CREBBP and CBFA2T3.
The importance of CREBBP is further strengthen by the
presence of a single SMZL case in the literature with a small
deletion that juxtaposes 16 exons of CREBBP with the ZNF434
gene, resulting in loss of the acetyltransferase domain of the
CREBBP protein [8]. Furthermore, we show the majority of
cases in our series carried mutations within MAPK signalling
genes, suggesting that mutations in these genes are strongly
associated with 7q-rearranged SMZL with IGHV1-2*04 usage.
Whilst our analysis identifies a series of novel genes mutated in
SMZL, a larger study is required to determine the frequency of
these events and any utility in the risk-adapted stratification of
SZML patients. To this aim, we are currently coordinating a
pan-European study into the presence of somatic mutations in
approx. 750 genes with a known or postulated role in SMZL
pathophysiology in a cohort of more than 300 SMZL cases.
This will ultimately establish the frequency and clinical
importance of gene mutations in SMZL and help to establish a
stratified approach to care including the possibility of targeted
therapy.
Table 2. Summary of the pathways in which mutated genes in our SMZL cohort can be found and their predicted functional
consequences.





   Nucleotide change   
Amino acid
change   consequences consequences 1 2 3 4 5 6 7
MAP kinase CACNA1E NM_001205293 c.G1069C p.E357Q Damaging Damaging     ✓    
 CACNA1H NM_021098 c.391delG p.E131fs Truncating Truncating   ✓     
 CACNA2D2 NM_001174051 c.2837delC p.P946fs Truncating Truncating   ✓      
 FLNC NM_001458 c.C3179T p.P1060L Damaging Probably damaging      ✓   
 MAP3K14 NM_003954 c.C200G p. A67G Truncating Truncating     ✓  ✓   
 MAPK8IP3 NM_001040439 c.743delA p.Q248fs Truncating Truncating   ✓      
 RASA1 NM_002890 c.C142A p. P48T Damaging Truncating       ✓  
 TAOK3 NM_016281 c.438-7-T) Splicing1 Truncating Truncating   ✓      
Notch NOTCH2 NM_024408 c.C7081T p.Q2361X Truncating Truncating      ✓   
   c.6836delA p.H2279fs Truncating Truncating ✓       
 PIWIL3 NM_001008496 c.2242delA p.T748fs Truncating Truncating   ✓      
 NOTCH4 NM_004557 c.C5877G p.C1959W Truncating Damaging       ✓  
 MAML3 NM_018717 c.1513_1514del p. 505_505del Truncating Truncating       ✓  
Cell cycle CUL1 NM_003592 c.T469G p.Y157D Damaging Probably damaging     ✓    
 CREBBP NM_001079846 c.A4349G p.Y1450C Damaging Truncating     ✓   ✓  
 CDC27 NM_001114091 c.A701C p. Y234S Tolerated Benign       ✓  
Cytokine-
cytokine FLT1 NM_002019 c.2594_splice splicing Truncating Truncating  ✓       
receptor
interaction CRLF2 NM_022148 c.G340C p.V114L Tolerated Probably damaging     ✓    
1 The TRRAP mutation in case 5 occurred within a splice-site and is predicted to resulted in aberrant splicing
2 Showed the presence (✓) and absence (white box) of each mutation in the patients in our series
doi: 10.1371/journal.pone.0083244.t002
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